Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -46.01% is 43% above its 5-year average of -80.31%, near the high end of its 5-year range (-168.70%–-18.22%).
23.87% above its 12-month average of -60.44%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -79.69%.
OPERATING MARGIN
-46.01%
OPERATING MARGIN AVG TTM
-60.44%
OPERATING MARGIN AVG 3Y
-75.18%
OPERATING MARGIN AVG 5Y
-80.31%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+23.87%
CURRENT VS 3Y AVG
+38.80%
CURRENT VS 5Y AVG
+42.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
908 Devices Inc.
Market Cap
$509.56M
Operating Margin
-46.01%
TTM Avg
-60.44%
3Y Avg
-75.18%
5Y Avg
-80.31%
Market Cap
$506.18M
Operating Margin
-1407.52%
TTM Avg
-703.76%
3Y Avg
-114341.22%
5Y Avg
-77223.74%
Market Cap
$503.93M
Operating Margin
0.00%
TTM Avg
-620906.82%
3Y Avg
-450471.78%
5Y Avg
-300340.85%
Market Cap
$515.90M
Operating Margin
-230460.98%
TTM Avg
-373160.49%
3Y Avg
-159952.53%
5Y Avg
-107112.87%
Market Cap
$500.41M
Operating Margin
10.00%
TTM Avg
8.23%
3Y Avg
4.46%
5Y Avg
2.51%
Market Cap
$497.37M
Operating Margin
0.00%
TTM Avg
-5335.57%
3Y Avg
-2667.78%
5Y Avg
-1778.52%
Market Cap
$521.71M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$486.39M
Operating Margin
-7.33%
TTM Avg
-12.79%
3Y Avg
-23.47%
5Y Avg
-68.20%
Market Cap
$530.71M
Operating Margin
-91.36%
TTM Avg
-296.77%
3Y Avg
-6281.52%
5Y Avg
-4187.68%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 908 Devices Inc. (MASS) | $509.56M | -46.01% | -60.44% | -75.18% | -80.31% |
| Crescent Biopharma, Inc. (CBIO)vs › | $506.18M | -1407.52% | -703.76% | -114341.22% | -77223.74% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | 0.00% | -620906.82% | -450471.78% | -300340.85% |
| Altimmune, Inc. (ALT)vs › | $515.90M | -230460.98% | -373160.49% | -159952.53% | -107112.87% |
| Tactile Systems Technology, Inc. (TCMD)vs › | $500.41M | 10.00% | 8.23% | 4.46% | 2.51% |
| Oculis Holding AG (OCS)vs › | $497.37M | 0.00% | -5335.57% | -2667.78% | -1778.52% |
| Immix Biopharma, Inc. (IMMX)vs › | $521.71M | 0.00% | 0.00% | 0.00% | 0.00% |
| Evolus, Inc. (EOLS)vs › | $486.39M | -7.33% | -12.79% | -23.47% | -68.20% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $530.71M | -91.36% | -296.77% | -6281.52% | -4187.68% |
| Puma Biotechnology, Inc. (PBYI)vs › | $485.58M | 13.16% | 14.88% | 13.50% | 6.84% |
Gross Margin
49.8%
Operating Margin
-46.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -79.69% |
| 2026-03-31 | -48.60% |
| 2025-12-31 | -18.22% |
| 2025-09-30 | -39.39% |
| 2025-06-30 | -116.31% |
| 2025-03-31 | -93.62% |
| 2024-12-31 | -107.61% |
| 2024-09-30 | -168.70% |
| 2024-06-30 | -74.50% |
| 2024-03-31 | -102.55% |
| 2023-12-31 | -67.68% |
| 2023-09-30 | -63.57% |
| 2023-06-30 | -90.45% |
| 2023-03-31 | -137.21% |
| 2022-12-31 | -88.79% |
| 2022-09-30 | -45.29% |
| 2022-06-30 | -75.36% |
| 2022-03-31 | -114.63% |
| 2021-12-31 | -22.27% |
| 2021-09-30 | -42.06% |
| 2021-06-30 | -90.07% |
| 2021-03-31 | -104.82% |
| 2020-12-31 | -67.97% |
| 2020-09-30 | -21.38% |
| 2020-06-30 | 19.12% |
| 2020-03-31 | -69.08% |
| 2019-12-31 | -3.70% |
| 2019-09-30 | -121.56% |
| 2019-06-30 | -122.92% |
| 2019-03-31 | -123.76% |
